Phase I trial of rebeccamycin analog (NSC #655649) in children with refractory solid tumors: A Pediatric Oncology Group study

Journal of Pediatric Hematology/Oncology

Volumn 25, Issue 7, 2003, Pages 526-533

  Langevin, Anne Marie ^a   Weitman, Steven D ^b   Kuhn, John G ^a   Weintraub, Susan T ^a   Baruchel, Sylvain ^c   Furman, Wayne ^d   Bernstein, Mark ^e   Blaney, Susan ^f   Vietti, Teresa ^g  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Ilex Oncology Inc   (United States)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e UNIVERSITY OF MONTREAL   (Canada)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Pediatric; Phase I trial; Rebeccamycin analog

Indexed keywords

1,11 DICHLORO 6 (2 DIETHYLAMINOETHYL) 12,13 DIHYDRO 5H INDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE 5,7(6H) DIONE 13 (4 O METHYLGLUCOSIDE); CYTOCHROME P450 ISOENZYME; DRUG METABOLITE; NSC 65549; REBECCAMYCIN; REBECCAMYCIN ANALOG; UNCLASSIFIED DRUG;

ADOLESCENT; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; FEMALE; FEVER; HEADACHE; HUMAN; LEUKOCYTE COUNT; LIVER TOXICITY; MALE; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM TOLERATED DOSE; MEAN RESIDENCE TIME; NEUTROPENIA; NEUTROPHIL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; SOLID TUMOR; THROMBOCYTOPENIA; VERTIGO;

ADOLESCENT; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTINEOPLASTIC; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; HEMOGLOBINS; HUMANS; INFANT; METABOLIC CLEARANCE RATE; NEOPLASMS; NEUTROPENIA; PATIENT SELECTION; PLATELET COUNT;

EID: 0038310028     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200307000-00006     Document Type: Article

References (18)

1. Kaneko T, Wong H, Utzig J, et al. Water-soluble derivatives of rebeccamycin. J Antibiotics. 1990;43:125-127.
2. Bush JA, Long BH, Catino JJ, et al. Production and biological activity of rebeccamycin, a novel antitumor agent. J Antibiotics. 1987;40:668-678.
3. 2+ dependent protein kinase. Biochem Biophys Res Commun. 1986;135:397-402.
4. Kase H, Iwahashi K, Matsuda Y. K252a, A potent inhibitor of protein kinase C from microbial origin. J Antibiot (Tokyo). 1986;39:1059-1065.
5. Schurig JE, Rose WC, Crosswell AR, et al. Experimental antitumor activity of BMY-27557, a new antitumor agent. Proc Am Assoc Cancer Res. 1990;31:416.
6. Weitman S, Moore R, Barrera H, et al. In vitro antitumor activity of rebeecamycin analog (NSC# 655649) against pediatric solid tumors. J Pediatr Hematol Oncol. 1998;20:136-139.
7. National Cancer Institute. Guidelines for Reporting of Adverse Drug Reactions. Bethesda, MD: Division of Cancer Treatment. National Cancer Institute; 1988.
8. Gibaldi M. Biopharmaceutics and Clinical Pharmacokinetics. 3d ed. Philadelphia: Lea & Febiger; 1984.
9. Cleary JF, Berlin JD, Tutsch KD, et al. Phase I clinical and pharmacokinetic Study of a rebeccamycin analog (NSC 655649). Proc Am Soc Clin Oncol. 1997;16:217a.
10. Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy. 1998;18:84-112.
11. Tolcher A, Eckhardt SG, Kuhn J, et al. Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties. J Clin Oncol. 2001;19:2937-2947.
12. Merchant J, Tutsch K, Dresen A, et al. Phase I clinical and pharmacokinetic Study of NSC 655649, a rebeccamycin analogue, given in both single-dose and multiple-dose formats. Clin Cancer Res. 2002;8:2193-2201.
13. Dowlati A, Hoppel CL, Ingalls ST, et al. Phase I clinical and pharmacokinetic study of rebeccamycin analog NSC 655649 given daily for five consecutive days. J Clin Oncol. 2001;19:2309-2318.
14. Blaney S, Seibel NL, O'Brien M, et al. Phase I trial of docetaxel administered as 1-hour infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute and Children's Cancer Group trial. J Clin Oncol. 1997;15:1538-1543.
15. Blaney S, Berg SL, Pratt C, et al. A phase I study of irinotecan in pediatric patients: a Pediatric Oncology Group study. Clin Cancer Res. 2001;7:32-37.
16. Eckhardt SG, Sharma S, Kuhn J, et al. A phase I and pharmacokinetics (PK) study of the rebeccamycin analog NSC 655649 in patients with advanced cancer. Proc Am Soc Clin Oncol. 1997;16:216a.
17. Langevin AM, Casto DT, Thomas PJ, et al. Phase I trial of 9-aminocamptothecin in children with refractory solid tumors: a Pediatric Oncology Group study. J Clin Oncol. 1998;16:2494-2499.
18. Stewart CF, Gajjar AJ, Heideman RL, et al. Phenytoin increases topotecan (TPT) clearance in a patient with medulloblastoma. Proc Am Soc Clin Oncol. 1997;16:251a.